Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names
New York, January 14, 2026, 13:46 EST — Regular session Shares of Structure Therapeutics (GPCR) jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares. This shift is crucial as investors wager the weight-loss craze will move from weekly injections to pills, reshaping the buyout landscape. A Novo Nordisk executive told Reuters that oral pills might claim “a third-plus” of the GLP-1 market by 2030. (Reuters) Deal rumors picked up steam on Wednesday after a Bloomberg report, highlighted by TheFly, quoted Novo Nordisk CEO Mike Doustdar saying, “We’re in